SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Why the future of marijuana legalization remains hazy despite high public support 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
RFK Jr. Spokesman Resigns Over Trump Administration’s Flavored E-Cigarette Policy 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
German healthcare and materials company Merck KGaA (NSE:PROR) announced on Monday that it has agreed to acquire U.S.-based biotech firm SpringWorks Therapeutics in a deal valued at approximately $3.9 billion. The acquisition is aimed at strengthening Merck’s oncology business and expanding its pipeline of cancer therapies.
The Darmstadt-headquartered group said it will pay $47 per share in cash for SpringWorks, representing a premium over the company’s recent trading price. The deal assigns SpringWorks an equity value of $3.9 billion and an enterprise value of around $3.4 billion (3.0 billion euros) after adjusting for the biotech firm's cash reserves.
SpringWorks Therapeutics specializes in developing targeted therapies for severe rare diseases and cancers, with its lead product, nirogacestat, positioned to treat desmoid tumors. The acquisition will give Merck access to a promising late-stage oncology asset and enhance its long-term growth prospects in the competitive cancer treatment market.
This move aligns with Merck's strategic focus on innovation and expanding its specialty medicine portfolio. The transaction is expected to strengthen its presence in the U.S. biotech sector and accelerate the development of novel oncology solutions for patients worldwide.
The acquisition is subject to customary closing conditions, including regulatory approvals, and is expected to finalize later this year.
